July 2010

Durable Complete Remission of Therapy-Refractory, Tumor-Stage Cutaneous T-Cell Lymphoma Under Radioimmunotherapy With Electron Beam Irradiation and Denileukin Diftitox

Author Affiliations

Author Affiliations: Departments of Dermatology (Drs Wobser, Lang, Ugurel, Bröcker, and Becker) and Radiotherapy (Drs Beckmann and Flentje), University Clinic of Würzburg, Würzburg, Germany; and Department of Dermatology, University Clinic of Magdeburg, Magdeburg, Germany (Dr Göppner).


Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(7):805-806. doi:10.1001/archdermatol.2010.147

Cutaneous T-cell lymphoma treated in the early stages has an excellent prognosis. However, in advanced stages, the prognosis is fatal; therapeutic response rates are low; and quality of life is severely reduced. Hence, a therapy that achieves a substantial and long-lasting down-staging of tumor burden in the advanced stages is warranted.

An 87-year-old man was seen with ulcerative skin tumors of the foot and erythematous plaques and patches. Histologic analysis revealed cutaneous T-cell lymphoma (mycosis fungoides) in tumor stage with a high proliferation index and a CD30 transformation. Further staging examinations were not indicative for systemic lymphoma. Subsequently, localized radiotherapy for the tumors in combination with methotrexate treatment, 20 mg/wk, achieved a complete remission.

First Page Preview View Large
First page PDF preview
First page PDF preview